RIBOLIFE-B
0693818AListed醫療健康 · 苏州瑞博生物技术股份有限公司是一家专注于小核酸药物研发的中国生物科技公司。
High attention
77.6
/100
- Offer price
- HK$57.97
- Final offer price
- HK$57.97
- Lot / entry fee
- 200 shares · HK$12K
- Proceeds
- HK$1.83B
- Sponsor
- CICC / Citigroup
- Est. margin oversub.
- 65.9x
- Public oversub.
- 101.1x
- One-lot win rate
- 1.7%
- First-day return
- +41.6%
Offer starts
Dec 31
Offer closes
Jan 6
Grey market
Jan 8
Listing
Jan 9
AI reference scoring and scenarios
After grey market
After grey market L1 heat score
77.6/ 100
Data coverage High
Target
Historical calibration
Listing-day trend
PositivePartial basis
Up probability
95.0%
First-day reference range
+19.2% – +71.1%
Published outcome check
First-day resultBig up+41.6%
Our call: Trend call valid
Covered 18/25 core factors
UsedMissingNot yet scorableN/A
Margin oversubscription
High heatOffer size
Weaker qualityCornerstone lockup
—Post-lockup offer value
—Recent same-rule trend
Neutral trendRecent same-type trend
Strong trendRecent sector trend
Strong trendValuation
Weak appealFundamental quality
Average qualityGrowth quality
—Profitability
Weak qualityCash runway
High qualityCustomer concentration
High riskCornerstone quality
—Sponsor record
Strong recordGreenshoe arrangementGreenshoe: yes · 15%
Average supportStabilizer track recordCICC
Strong recordA-share pre-grey trend
—A-share listing-day trend
—Public oversubscription
High heatOne-lot win rate
High heatInternational placing
High heatFinal pricing position
—Actual greenshoe useCumulative use 0.0%
Good supportGrey market return
Strong trendThe assessment and probability ranges are informational only and are not investment advice.
AI Research Report
After grey marketThe analysis report for this IPO is being generated.